<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783950</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2016.020</org_study_id>
    <secondary_id>CU 008</secondary_id>
    <secondary_id>HUM00110858</secondary_id>
    <nct_id>NCT02783950</nct_id>
  </id_info>
  <brief_title>Genomics in Michigan Impacting Observation or Radiation</brief_title>
  <acronym>G-MINOR</acronym>
  <official_title>Genomics in Michigan Impacting Observation or Radiation (G-MINOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michigan Urological Surgery Improvement Collaborative (MUSIC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GenomeDx Biosciences Corp</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk&#xD;
      post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to&#xD;
      clinical factors alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized trial will compare the receipt of adjuvant therapy for high-risk&#xD;
      radical prostatectomy (RP) patients who undergo Decipher testing to those who do not. 350&#xD;
      subjects from within the statewide Michigan Urological Surgery Improvement Collaborative&#xD;
      (MUSIC) will be randomized to either a Genomic Classifier (Decipher) or Usual-Care-Based (UC)&#xD;
      strategy for a period of three months. If enrolled during the Genomic Classifier period, both&#xD;
      subjects and their treating physician will be provided Decipher results and CAPRA-S scores.&#xD;
      In the UC periods, CAPRA-S scores but not Decipher results will be provided.&#xD;
&#xD;
      The enrollment goal, initially and throughout the study, was to enroll 350 evaluable&#xD;
      patients. During the study, the target accrual goal was raised to 550 patients to allow more&#xD;
      flexibility among sites to achieve the enrollment goal of 350 evaluable patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Receive Adjuvant Therapy (Radiation and/or Hormone Therapy)</measure>
    <time_frame>within 18 months of radical prostatectomy</time_frame>
    <description>Adjuvant will be defined as preceding biochemical recurrence (BCR) (i.e.: PSA ≥ 0.2 ng/ml) and within 18 months of radical prostatectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time (From Randomization) to Adjuvant Treatment Administration</measure>
    <time_frame>Up to 18 months post randomization</time_frame>
    <description>Adjuvant treatment (radiation and/or hormone) is defined as preceding BCR. BCR occurs when prostate specific antigen (PSA) ≥ 0.2 ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (From Randomization) to Salvage Treatment Administration</measure>
    <time_frame>Up to 5 years post randomization</time_frame>
    <description>Salvage treatment (radiation and/or hormone therapy) is defined as either after BCR or &gt;18 months after surgery in the absence of documented BCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (From Randomization) to Biochemical Recurrence (BCR)</measure>
    <time_frame>Up to 5 years post randomization</time_frame>
    <description>BCR is defined as PSA ≥ 0.2 ng/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (From Randomization) to Metastatic Disease (Regional or Distant)</measure>
    <time_frame>Up to 5 years post randomization</time_frame>
    <description>Metastasis is determined based on CT, MRI, bone scan, and/or positron emission tomography (PET) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Michigan Urological Surgery Improvement Collaborative (MUSIC) Patient Reported Outcomes (PRO)</measure>
    <time_frame>Up to 24 months post radical prostatectomy</time_frame>
    <description>Composite Expanded Prostate Cancer Index Composite (EPIC)-26 domain scores for a) urinary irritative function, b) urinary incontinence, and c) sexual function will be measured at baseline and 24 months post-radical prostatectomy. Each of the 3 domains is scaled from 0-100 (higher is better).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">356</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>GC (Decipher) Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual-Care-Based (UC) Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>If enrolled during the UC period, only the CAPRA-S results will be provided.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Decipher Prostate Cancer Classifier</intervention_name>
    <description>The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.</description>
    <arm_group_label>GC (Decipher) Arm</arm_group_label>
    <other_name>Decipher Post-Op</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prostate cancer patients who have undergone radical prostatectomy&#xD;
&#xD;
          -  PSA &lt; 0.1 ng/ml at enrollment&#xD;
&#xD;
          -  At least one of the following:&#xD;
&#xD;
               -  pT3 (seminal vesicle invasion or extraprostatic extension), or&#xD;
&#xD;
               -  Positive surgical margins&#xD;
&#xD;
          -  Radical prostatectomy within one year of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals who have any of the following will not be eligible to participate:&#xD;
&#xD;
               -  Have regional or distant metastatic disease&#xD;
&#xD;
               -  Received any radiation or hormone therapy (neo-adjuvant, adjuvant, or salvage)&#xD;
&#xD;
               -  Node positive&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Morgan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Cher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Hospital and Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates of Grand Rapids</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Urological Clinic</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Medical Group- Urology</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Surgeons, PC</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Medical Center, PLLC</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-City Urology</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Urology Associates, PC</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Urology-Town Center</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHA Urology at St. Joe's Ann Arbor</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://musicurology.com/</url>
    <description>Website for MUSIC</description>
  </link>
  <link>
    <url>http://www.genomedx.com</url>
    <description>Website for GenomeDx Biosciences (study sponsor)</description>
  </link>
  <reference>
    <citation>Adams G, Gulliford MC, Ukoumunne OC, Eldridge S, Chinn S, Campbell MJ. Patterns of intra-cluster correlation from primary care research to inform study design and analysis. J Clin Epidemiol. 2004 Aug;57(8):785-94. Review.</citation>
    <PMID>15485730</PMID>
  </reference>
  <reference>
    <citation>Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra AP, Wood PJ, Hornberger J. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget. 2013 Apr;4(4):600-9.</citation>
    <PMID>23592338</PMID>
  </reference>
  <reference>
    <citation>Buja, A., Hastie, T. J. and Tibshirani, R. J. (1989). Linear smoothers and additive models (with discussion). Annals of Statistics, 17, 453-555.</citation>
  </reference>
  <reference>
    <citation>Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. BJU Int. 2015 Mar;115(3):419-29. doi: 10.1111/bju.12789. Epub 2014 Aug 11.</citation>
    <PMID>24784420</PMID>
  </reference>
  <reference>
    <citation>Campbell, Michael J., and Stephen J. Walters. How to Design, Analyse and Report Cluster Randomised Trials in Medicine and Health Related Research. John Wiley &amp; Sons, 2014.</citation>
  </reference>
  <reference>
    <citation>Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013.</citation>
    <PMID>23826159</PMID>
  </reference>
  <reference>
    <citation>Heo M, Leon AC. Comparison of statistical methods for analysis of clustered binary observations. Stat Med. 2005 Mar 30;24(6):911-23.</citation>
    <PMID>15558576</PMID>
  </reference>
  <reference>
    <citation>Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013 Dec;190(6):2047-53. doi: 10.1016/j.juro.2013.06.017. Epub 2013 Jun 11.</citation>
    <PMID>23770138</PMID>
  </reference>
  <reference>
    <citation>Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1038-1046. doi: 10.1016/j.ijrobp.2014.04.052. Epub 2014 Jul 8.</citation>
    <PMID>25035207</PMID>
  </reference>
  <reference>
    <citation>Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.</citation>
    <PMID>24998118</PMID>
  </reference>
  <reference>
    <citation>Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol. 2015 Apr;67(4):778-86. doi: 10.1016/j.eururo.2014.10.036. Epub 2014 Nov 12.</citation>
    <PMID>25466945</PMID>
  </reference>
  <reference>
    <citation>Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015 Mar 10;33(8):944-51. doi: 10.1200/JCO.2014.59.0026. Epub 2015 Feb 9. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416.</citation>
    <PMID>25667284</PMID>
  </reference>
  <reference>
    <citation>Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, Han M, Partin AW, Trock BJ, Schaeffer EM. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. Eur Urol. 2016 Jan;69(1):157-65. doi: 10.1016/j.eururo.2015.05.042. Epub 2015 Jun 6.</citation>
    <PMID>26058959</PMID>
  </reference>
  <reference>
    <citation>Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol. 2015 Sep 1;33(25):2789-96. doi: 10.1200/JCO.2014.59.8912. Epub 2015 Jul 20.</citation>
    <PMID>26195723</PMID>
  </reference>
  <reference>
    <citation>Lake S, Kammann E, Klar N, Betensky R. Sample size re-estimation in cluster randomization trials. Stat Med. 2002 May 30;21(10):1337-50.</citation>
    <PMID>12185888</PMID>
  </reference>
  <reference>
    <citation>Michalopoulos SN, Kella N, Payne R, Yohannes P, Singh A, Hettinger C, Yousefi K, Hornberger J; PRO-ACT Study Group. Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study. Curr Med Res Opin. 2014 Aug;30(8):1547-56. doi: 10.1185/03007995.2014.919908. Epub 2014 May 15.</citation>
    <PMID>24803160</PMID>
  </reference>
  <reference>
    <citation>Nguyen PL, Shin H, Yousefi K, Thompson DJ, Hornberger J, Hyatt AS, Badani KK, Morgan TM, Feng FY. Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. Urology. 2015 Jul;86(1):35-40. doi: 10.1016/j.urology.2015.04.004.</citation>
    <PMID>26142578</PMID>
  </reference>
  <reference>
    <citation>Lobo JM, Dicker AP, Buerki C, Daviconi E, Karnes RJ, Jenkins RB, Patel N, Den RB, Showalter TN. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. PLoS One. 2015 Apr 2;10(3):e0116866. doi: 10.1371/journal.pone.0116866. eCollection 2015.</citation>
    <PMID>25837660</PMID>
  </reference>
  <reference>
    <citation>Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009 Mar;181(3):956-62. doi: 10.1016/j.juro.2008.11.032. Epub 2009 Jan 23.</citation>
    <PMID>19167731</PMID>
  </reference>
  <reference>
    <citation>Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006 Nov-Dec;26(6):565-74.</citation>
    <PMID>17099194</PMID>
  </reference>
  <reference>
    <citation>Wu S, Crespi CM, Wong WK. Comparison of methods for estimating the intraclass correlation coefficient for binary responses in cancer prevention cluster randomized trials. Contemp Clin Trials. 2012 Sep;33(5):869-80. doi: 10.1016/j.cct.2012.05.004. Epub 2012 May 22.</citation>
    <PMID>22627076</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <results_first_submitted>February 3, 2021</results_first_submitted>
  <results_first_submitted_qc>February 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 25, 2021</results_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genomics</keyword>
  <keyword>Adjuvant Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02783950/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GC (Decipher) Arm</title>
          <description>If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.</description>
        </group>
        <group group_id="P2">
          <title>Usual-Care-Based (UC) Arm</title>
          <description>If enrolled during the UC period, only the CAPRA-S results will be provided.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GC (Decipher) Arm</title>
          <description>If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.</description>
        </group>
        <group group_id="B2">
          <title>Usual-Care-Based (UC) Arm</title>
          <description>If enrolled during the UC period, only the CAPRA-S results will be provided.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="182"/>
            <count group_id="B2" value="174"/>
            <count group_id="B3" value="356"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="6.5"/>
                    <measurement group_id="B2" value="64.6" spread="6.3"/>
                    <measurement group_id="B3" value="64.7" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Specific Antigen</title>
          <units>ng/ML</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" lower_limit="1.1" upper_limit="40.2"/>
                    <measurement group_id="B2" value="6.0" lower_limit="1.5" upper_limit="30.5"/>
                    <measurement group_id="B3" value="6.4" lower_limit="1.1" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Receive Adjuvant Therapy (Radiation and/or Hormone Therapy)</title>
        <description>Adjuvant will be defined as preceding biochemical recurrence (BCR) (i.e.: PSA ≥ 0.2 ng/ml) and within 18 months of radical prostatectomy.</description>
        <time_frame>within 18 months of radical prostatectomy</time_frame>
        <population>Includes all patients who were followed for at least 18 months or had an event prior to 18 months</population>
        <group_list>
          <group group_id="O1">
            <title>GC (Decipher) Arm</title>
            <description>If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.</description>
          </group>
          <group group_id="O2">
            <title>Usual-Care-Based (UC) Arm</title>
            <description>If enrolled during the UC period, only the CAPRA-S results will be provided.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Receive Adjuvant Therapy (Radiation and/or Hormone Therapy)</title>
          <description>Adjuvant will be defined as preceding biochemical recurrence (BCR) (i.e.: PSA ≥ 0.2 ng/ml) and within 18 months of radical prostatectomy.</description>
          <population>Includes all patients who were followed for at least 18 months or had an event prior to 18 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (From Randomization) to Adjuvant Treatment Administration</title>
        <description>Adjuvant treatment (radiation and/or hormone) is defined as preceding BCR. BCR occurs when prostate specific antigen (PSA) ≥ 0.2 ng/ml.</description>
        <time_frame>Up to 18 months post randomization</time_frame>
        <population>Population includes patients who had adjuvant treatment</population>
        <group_list>
          <group group_id="O1">
            <title>GC (Decipher) Arm</title>
            <description>If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.</description>
          </group>
          <group group_id="O2">
            <title>Usual-Care-Based (UC) Arm</title>
            <description>If enrolled during the UC period, only the CAPRA-S results will be provided.</description>
          </group>
        </group_list>
        <measure>
          <title>Time (From Randomization) to Adjuvant Treatment Administration</title>
          <description>Adjuvant treatment (radiation and/or hormone) is defined as preceding BCR. BCR occurs when prostate specific antigen (PSA) ≥ 0.2 ng/ml.</description>
          <population>Population includes patients who had adjuvant treatment</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" lower_limit="169" upper_limit="474"/>
                    <measurement group_id="O2" value="233.5" lower_limit="65" upper_limit="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Wilcoxon Rank Test p-value</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (From Randomization) to Salvage Treatment Administration</title>
        <description>Salvage treatment (radiation and/or hormone therapy) is defined as either after BCR or &gt;18 months after surgery in the absence of documented BCR</description>
        <time_frame>Up to 5 years post randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (From Randomization) to Biochemical Recurrence (BCR)</title>
        <description>BCR is defined as PSA ≥ 0.2 ng/ml.</description>
        <time_frame>Up to 5 years post randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (From Randomization) to Metastatic Disease (Regional or Distant)</title>
        <description>Metastasis is determined based on CT, MRI, bone scan, and/or positron emission tomography (PET) scan</description>
        <time_frame>Up to 5 years post randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Michigan Urological Surgery Improvement Collaborative (MUSIC) Patient Reported Outcomes (PRO)</title>
        <description>Composite Expanded Prostate Cancer Index Composite (EPIC)-26 domain scores for a) urinary irritative function, b) urinary incontinence, and c) sexual function will be measured at baseline and 24 months post-radical prostatectomy. Each of the 3 domains is scaled from 0-100 (higher is better).</description>
        <time_frame>Up to 24 months post radical prostatectomy</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GC (Decipher) Arm</title>
          <description>If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.</description>
        </group>
        <group group_id="E2">
          <title>Usual-Care-Based (UC) Arm</title>
          <description>If enrolled during the UC period, only the CAPRA-S results will be provided.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Todd Morgan, MD</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-647-8902</phone>
      <email>tomorgan@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

